NASDAQ · ATLN
Atlantic International Corp.
$0.90$0.00 (0.0%)
Atlantic International Corp.’s quoted price sits in the lower half of its reported 52-week range, 82.86% below the high.
Loading market information…
NASDAQ · KERN · USD
Stock price, earnings
Quote as of Feb 8, 2024, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Akerna Corp.’s quoted price sits in the lower half of its reported 52-week range, 98.46% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Akerna Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Akerna Corp., a Denver, Colorado-based company established in 2010, develops and provides sophisticated enterprise software solutions. These solutions primarily cater to businesses in the United States and Canada, enabling robust regulatory compliance and efficient inventory management. Their product portfolio includes MJ Platform, specifically designed for the burgeoning cannabis, hemp, and CBD industries, and Leaf Data Systems, a dedicated regulatory software for government agencies. A cornerstone of their offerings is a comprehensive "seed-to-sale" platform. This technology furnishes cultivators, processors, retailers, and clinics within the cannabis sector with essential tools for tracking, reporting, and maintaining compliance throughout the entire supply chain, extending to what they term 'seed-to-sale-to-self' data. Akerna further extends its expertise through consulting services for the cannabis industry, alongside offerings in business intelligence, data analytics, and other software-related support. Additionally, they offer Last Call Analytics, a distinct tool that assists alcohol brands in scrutinizing their retail sales performance.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:41 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2022 |
|---|
| Aug 10, 2022 |
| -$16.60-591.67% vs estimate |
| $6.09M-13.55% vs estimate |
| Q1 2022 | May 9, 2022 | -$13.80-305.88% vs estimate | $6.95M-46.03% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.90$0.00 (0.0%)
Atlantic International Corp.’s quoted price sits in the lower half of its reported 52-week range, 82.86% below the high.
$0.42+$0.42 (+100.0%)
CareMax, Inc.’s quoted price sits in the lower half of its reported 52-week range, 18.94% below the high.
$0.50$0.00 (0.0%)
TC Biopharm (Holdings) Plc’s quoted price sits in the lower half of its reported 52-week range, 99.9% below the high.
$0.37$0.00 (0.0%)
Seelos Therapeutics, Inc.: Healthcare · Biotechnology.
$0.16+$0.02 (+12.4%)
Virios Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.4% below the high.
$0.01-$0.01 (-36.84%)
Bellerophon Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.0% below the high.
$0.02$0.00 (0.0%)
Histogen Inc.: Healthcare · Biotechnology.
$0.09-$0.01 (-10.1%)
FSD Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.92% below the high.
